{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T16:38:45Z","timestamp":1790872725638,"version":"4.1.0"},"reference-count":29,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transplantation Proceedings"],"published-print":{"date-parts":[[2023,11]]},"DOI":"10.1016\/j.transproceed.2023.08.021","type":"journal-article","created":{"date-parts":[[2023,9,29]],"date-time":"2023-09-29T16:02:23Z","timestamp":1696003343000},"page":"2035-2040","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Significant Increase in Cytomegalovirus (CMV) Infection in Solid Organ Transplants Associated With Increased Use of Thymoglobulin as Induction Therapy?"],"prefix":"10.1016","volume":"55","author":[{"given":"Elen Almeida","family":"Romao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aparecida Yulie","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gilberto Gambero","family":"Gaspar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tania Marisa Pisi","family":"Garcia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valmir Aparecido","family":"Muglia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Estela Papini","family":"Nardin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos Augusto Fernandes","family":"Molina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Viviane Cristina Teixeira Pedroso","family":"de Figueiredo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1351-4775","authenticated-orcid":false,"given":"Miguel","family":"Moyses-Neto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.transproceed.2023.08.021_bib0001","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1097\/TP.0000000000002191","article-title":"The third international consensus guidelines on the management of cytomegalovirus in solid-organ transplantation","volume":"102","author":"Kotton","year":"2018","journal-title":"Transplantation"},{"key":"10.1016\/j.transproceed.2023.08.021_bib0002","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1097\/TP.0000000000000160","article-title":"Cytomegalovirus serology and replication remain associated with solid organ graft rejection and graft loss in the era of prophylactic treatment","volume":"98","author":"2-Stern","year":"2014","journal-title":"Transplantation"},{"key":"10.1016\/j.transproceed.2023.08.021_bib0003","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1111\/ajt.12006","article-title":"CMV: prevention, diagnosis, and therapy","volume":"13","author":"Kotton","year":"2013","journal-title":"Am J Transpl"},{"key":"10.1016\/j.transproceed.2023.08.021_bib0004","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1111\/j.1523-1755.2004.00735.x","article-title":"Impact of early cytomegalovirus infection and disease on long-term recipient and kidney graft survival","volume":"66","author":"Sagedal","year":"2004","journal-title":"Kidney Int"},{"key":"10.1016\/j.transproceed.2023.08.021_bib0005","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1111\/j.1600-6143.2004.00382.x","article-title":"Efficacy and safety of valganciclovir vs. oral ganciclovir for prevention of cytomegalovirus disease in solid organ transplant recipients","volume":"4","author":"Paya","year":"2004","journal-title":"Am J Transplant"},{"key":"10.1016\/j.transproceed.2023.08.021_bib0006","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1111\/j.1600-6143.2010.03074.x","article-title":"The efficacy and safety of 200 days valganciclovir cytomegalovirus prophylaxis in high-risk kidney transplant recipients","volume":"10","author":"6-Humar","year":"2010","journal-title":"Am J Transplant"},{"key":"10.1016\/j.transproceed.2023.08.021_bib0007","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1097\/TP.0000000000002024","article-title":"Valganciclovir prophylaxis versus preemptive therapy in cytomegalovirus-positive renal allograft recipients: long-term results after 7 years of a randomized clinical trial","volume":"102","author":"Witzke","year":"2018","journal-title":"Transplantation"},{"key":"10.1016\/j.transproceed.2023.08.021_bib0008","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1053\/j.ajkd.2011.04.010","article-title":"Human cytomegalovirus and kidney transplantation: a clinician's update","volume":"58","author":"De Keyzer","year":"2011","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.transproceed.2023.08.021_bib0009","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1097\/TP.0000000000000189","article-title":"A double-blinded, prospective study to define antigenemia and quantitative real-time polymerase chain reaction cutoffs to start preemptive therapy in low-risk, seropositive, renal transplanted recipients","volume":"98","author":"David-Neto","year":"2014","journal-title":"Transplantation"},{"key":"10.1016\/j.transproceed.2023.08.021_bib0010","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.jiph.2018.07.001","article-title":"Seroprevalence of Toxoplasma gondii, cytomegalovirus and Epstein Barr virus in 578 tissue donors in Brazil","volume":"12","author":"Tuon","year":"2019","journal-title":"J Infect Public Health"},{"key":"10.1016\/j.transproceed.2023.08.021_bib0011","doi-asserted-by":"crossref","first-page":"2134","DOI":"10.1111\/j.1600-6143.2006.01413.x","article-title":"Prophylatic versus preemptive oral valganciclovir for the management of cytomegalovirus infection in adult renal transplant recipients","volume":"6","author":"Khoury","year":"2006","journal-title":"Am J Transpl"},{"key":"10.1016\/j.transproceed.2023.08.021_bib0012","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1111\/j.1600-6143.2007.02031.x","article-title":"Valacyclovir prophylaxis versus preemptive valganciclovir therapy to prevent cytomegalovirus disease after renal transplantation","volume":"8","author":"Reischig","year":"2008","journal-title":"Am J Transplant"},{"key":"10.1016\/j.transproceed.2023.08.021_bib0013","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1097\/TP.0b013e318238dab3","article-title":"Valganciclovir prophylaxis versus preemptive therapy in cytomegalovirus-positive renal allograft recipients:1-year results of a randomized clinical trial","volume":"93","author":"Witzke","year":"2012","journal-title":"Transplantation"},{"key":"10.1016\/j.transproceed.2023.08.021_bib0014","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1016\/j.bjid.2016.08.007","article-title":"Target preemptive therapy according to perceived risk of CMV infection after kidney transplantation","volume":"20","author":"Pinto","year":"2016","journal-title":"Braz J Infectious Dis"},{"key":"10.1016\/j.transproceed.2023.08.021_bib0015","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1086\/324516","article-title":"Allograft rejection predicts the occurrence of late-onset cytomegalovirus (CMV) disease among CMV-mismatched solid organ transplant patients receiving prophylaxis with oral ganciclovir","volume":"184","author":"Razonable","year":"2001","journal-title":"J Infect Dis"},{"key":"10.1016\/j.transproceed.2023.08.021_bib0016","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1016\/j.transproceed.2017.02.019","article-title":"Pre-emptive therapy fpr the treatment pf cytomegalovirus after kidney transplantation","volume":"49","author":"Pretagostini","year":"2017","journal-title":"Transpl Proceedings"},{"key":"10.1016\/j.transproceed.2023.08.021_bib0017","doi-asserted-by":"crossref","first-page":"817","DOI":"10.7326\/0003-4819-128-10-199805150-00004","article-title":"The effect of antilymphocyte induction therapy on renal allograft survival. A meta-analysis of individual patient-level data. Anti-Lymphocyte Antibody Induction Therapy Study Group","volume":"128","author":"Szczech","year":"1998","journal-title":"Annals of Internal Medicine"},{"key":"10.1016\/j.transproceed.2023.08.021_bib0018","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1097\/TP.0b013e3181fecfcb","article-title":"Induction immunosuppression improves long-term graft and patient outcome in organ transplantation: an analysis of United Network for Organ Sharing registry data","volume":"90","author":"Cai","year":"2010","journal-title":"Transplantation"},{"key":"10.1016\/j.transproceed.2023.08.021_bib0019","article-title":"Polyclonal and monoclonal antibodies for induction therapy in kidney transplant recipients","volume":"1","author":"Hill","year":"2017","journal-title":"Cochrane Database System Rev"},{"key":"10.1016\/j.transproceed.2023.08.021_bib0020","doi-asserted-by":"crossref","first-page":"2139","DOI":"10.1097\/TP.0000000000003124","article-title":"The influence of antithymocyte globulin dose on the incidence of CMV infection in high-risk kidney transplant recipients without pharmacological prophylaxis","volume":"104","author":"Paula","year":"2019","journal-title":"Transplantation"},{"key":"10.1016\/j.transproceed.2023.08.021_bib0021","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1097\/TP.0b013e3181b6f38c","article-title":"Reduced dose rabbit anti-thymocyte globulin induction for prevention of acute rejection in high-risk kidney transplant recipients","volume":"88","author":"Klem","year":"2009","journal-title":"Transplantation"},{"key":"10.1016\/j.transproceed.2023.08.021_bib0022","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1097\/TP.0b013e31816dd596","article-title":"thymoglobulin dose optimization for induction therapy in high risk kidney transplant recipients","volume":"85","author":"Gurk-Turner","year":"2008","journal-title":"Transplantation"},{"key":"10.1016\/j.transproceed.2023.08.021_bib0023","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1111\/j.1432-2277.2011.01321.x","article-title":"The risk of cytomegalovirus recurrence after kidney transplantation","volume":"24","author":"Iilka","year":"2011","journal-title":"Transplant International"},{"key":"10.1016\/j.transproceed.2023.08.021_bib0024","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1097\/TP.0000000000001338","article-title":"Recurrence of CMV infection and the effect of prolonged antivirals in organ transplant recipients","volume":"101","author":"Natori","year":"2017","journal-title":"Transplantation"},{"key":"10.1016\/j.transproceed.2023.08.021_bib0025","doi-asserted-by":"crossref","first-page":"S15","DOI":"10.1097\/01.tp.0000230460.42558.b0","article-title":"The natural course of cytomegalovirus infection and disease in renal transplant recipients","volume":"82","author":"Hartmann","year":"2006","journal-title":"Transplantation"},{"key":"10.1016\/j.transproceed.2023.08.021_bib0026","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1111\/tri.13667","article-title":"Clinical consequences of primary CMV infection after renal transplantation: a case-control study","volume":"33","author":"Singh","year":"2020","journal-title":"Transplant International"},{"key":"10.1016\/j.transproceed.2023.08.021_bib0027","doi-asserted-by":"crossref","first-page":"473","DOI":"10.3390\/pathogens10040473","article-title":"Cytomegalovirus disease in renal transplanted patients: prevalence, determining factors, and influence on graft and patients outcomes","volume":"10","author":"Alfieri","year":"2021","journal-title":"Pathogens"},{"key":"10.1016\/j.transproceed.2023.08.021_bib0028","doi-asserted-by":"crossref","first-page":"e12732","DOI":"10.1111\/tid.12732","article-title":"Burden of cytomegalovirus disease in solid organ transplant recipients: a national matched cohort study in an inpatient setting","volume":"19","author":"Hakimi","year":"2017","journal-title":"Transpl Infect Dis"},{"key":"10.1016\/j.transproceed.2023.08.021_bib0029","doi-asserted-by":"crossref","first-page":"131","DOI":"10.12659\/AOT.895677","article-title":"Cytomegalovirus (CMV) monitoring after liver transplantation: comparison of CMV Pp65 antigenemia assay with Real-Time PCR calibrated to Who International Standard","volume":"21","author":"Kamel","year":"2016","journal-title":"Ann Transpl"}],"container-title":["Transplantation Proceedings"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S004113452300564X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S004113452300564X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T21:46:48Z","timestamp":1758577608000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S004113452300564X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11]]},"references-count":29,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2023,11]]}},"alternative-id":["S004113452300564X"],"URL":"https:\/\/doi.org\/10.1016\/j.transproceed.2023.08.021","relation":{},"ISSN":["0041-1345"],"issn-type":[{"value":"0041-1345","type":"print"}],"subject":[],"published":{"date-parts":[[2023,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Significant Increase in Cytomegalovirus (CMV) Infection in Solid Organ Transplants Associated With Increased Use of Thymoglobulin as Induction Therapy?","name":"articletitle","label":"Article Title"},{"value":"Transplantation Proceedings","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.transproceed.2023.08.021","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}